

Join us at the **Pfizer**-sponsored symposium at

ESICM 2022



Suspect early and treat decisively: clinical dilemmas that delay appropriate antimicrobial treatment

Monday, 24th October 2022
12:30–13:30 (CEST)
Amphitheatre Bordeaux, level 3

Join our esteemed faculty as they highlight the challenging scenarios that ICU physicians face with MDR Gram-negative bacterial infections and respiratory virus-associated IMDs (invasive mould disease) that complicate patient care. Using patient case studies, our panel members will share considerations to improve the time to early and appropriate treatment and illustrate the value of a diagnostics-driven approach, with the aim of improving clinical outcomes in critically ill patients.

Meet Our Faculty



George Dimopoulos (Chair)

Department of Critical Care Medicine,
Evgenidio Hospital, National and
Kapodistrian University of Athens (NKUA),
Athens, Greece



Paula Ramírez

Intensive Care Unit,
Hospital University and Polytechnic La Fe,
Valencia, Spain



Malgorzata Mikulska

Department of Health Sciences (DISSAL),
University of Genova, Genova, Italy
Infectious Diseases Unit,
San Martino Policlinico Hospital-IRCCS,
Genova, Italy

Agenda | Chair: George Dimopoulos, Greece

| | | |
|---------|--|-------------------------------|
| 12:30 » | Welcome and introduction: Is your threshold for suspecting bacterial or fungal infections too high? | George Dimopoulos, Greece |
| 12:35 » | Acting on suspicion of an MDR Gram-negative bacterial infection: What treatment, when? | Paula Ramírez, Spain |
| 12:55 » | Managing respiratory virus-associated IMD in the ICU: The value of a diagnostic-driven approach | Malgorzata Mikulska, Italy |
| 13:15 » | Panel discussion: To treat our patients early and appropriately, what is the optimal approach? | All faculty |
| 13:25 » | Reflection points and close | George Dimopoulos, Greece |

ICU, intensive care unit; IMD, invasive mould disease; MDR, multidrug-resistant.

To access our information notice on personal data for healthcare professionals, please visit the following link: <https://privacycenter.pfizer.com/fr/hcp>. If you would like to report an adverse event related to a Pfizer group product, please contact the pharmacovigilance department by e-mail at FRA.AEReporting@pfizer.com. Pfizer. Simplified joint-stock company with capital of €47,570. Head office 23-25 avenue du Docteur Lannelongue -75014 Paris. 433 623 550 RCS Paris. Lessee-manager of Pfizer Holding France.

This symposium is initiated, organised and funded by Pfizer Inc.
PP-UNP-GLB-0513; September 2022.
©2022 Pfizer Inc. All rights reserved.

